Precision Biologics is a clinical-stage biotechnology company developing tumor-specific monoclonal antibodies (mAbs) and companion diagnostics for solid-tumor cancers. The company leverages a proprietary library of cancer vaccines, antigens, and antibodies derived from surgically removed human tumors to create therapies intended to activate tumor- and disease-specific immune responses while sparing healthy cells. Its lead therapeutic antibody recently completed accrual to a Phase 2a trial for advanced pancreatic and colorectal cancer, and a multi-center randomized Phase 2b trial for advanced pancreatic cancer is currently enrolling at several U.S. academic medical centers. The pancreatic cancer antibody has demonstrated promising early Phase 2 data and received Orphan Drug status. The pipeline also includes two additional proprietary antibodies that bind tumor-specific antigens found in pancreatic, colorectal and several other types of cancer. Precision Biologics plans to combine its platform with diagnostic and immunotherapy technologies available at NantWorks and NantOmics to accelerate discovery and development.

Total raised

$50M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2015